Protamine-Based Strategies for RNA Transfection.
RNA
cancer therapy
protamine
transfection
vaccines
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
14 Jun 2021
14 Jun 2021
Historique:
received:
23
04
2021
revised:
28
05
2021
accepted:
03
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Protamine is a natural cationic peptide mixture mostly known as a drug for the neutralization of heparin and as a compound in formulations of slow-release insulin. Protamine is also used for cellular delivery of nucleic acids due to opposite charge-driven coupling. This year marks 60 years since the first use of Protamine as a transfection enhancement agent. Since then, Protamine has been broadly used as a stabilization agent for RNA delivery. It has also been involved in several compositions for RNA-based vaccinations in clinical development. Protamine stabilization of RNA shows double functionality: it not only protects RNA from degradation within biological systems, but also enhances penetration into cells. A Protamine-based RNA delivery system is a flexible and versatile platform that can be adjusted according to therapeutic goals: fused with targeting antibodies for precise delivery, digested into a cell penetrating peptide for better transfection efficiency or not-covalently mixed with functional polymers. This manuscript gives an overview of the strategies employed in protamine-based RNA delivery, including the optimization of the nucleic acid's stability and translational efficiency, as well as the regulation of its immunostimulatory properties from early studies to recent developments.
Identifiants
pubmed: 34198550
pii: pharmaceutics13060877
doi: 10.3390/pharmaceutics13060877
pmc: PMC8231816
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Exp Med. 1996 Aug 1;184(2):465-72
pubmed: 8760800
Eur J Immunol. 2000 Jan;30(1):1-7
pubmed: 10602021
Drug Deliv. 2020 Dec;27(1):1231-1235
pubmed: 32804028
Nat Rev Drug Discov. 2009 Feb;8(2):129-38
pubmed: 19180106
Oncol Lett. 2019 Dec;18(6):5897-5904
pubmed: 31788063
Eur J Pharm Biopharm. 2010 Nov;76(3):384-93
pubmed: 20691262
Sci Rep. 2016 Sep 08;6:32301
pubmed: 27604151
Adv Enzymol Relat Areas Mol Biol. 1974;41(0):99-128
pubmed: 4609051
Eur J Pharm Biopharm. 2011 Nov;79(3):495-502
pubmed: 21726641
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4095-100
pubmed: 17360483
Eur J Immunol. 2006 Oct;36(10):2807-16
pubmed: 17013976
EMBO Rep. 2010 Mar;11(3):153-60
pubmed: 20168329
J Control Release. 2012 Aug 10;161(3):875-83
pubmed: 22762887
Hepatology. 1998 Mar;27(3):772-8
pubmed: 9500706
Methods Mol Biol. 2017;1499:155-163
pubmed: 27987148
Cell Mol Life Sci. 2009 Sep;66(17):2873-96
pubmed: 19499185
Methods Mol Biol. 2017;1499:89-107
pubmed: 27987144
Nature. 1978 Jan 12;271(5641):130-5
pubmed: 622153
Mol Biol Biochem Biophys. 1973;12(0):1-114
pubmed: 4607555
Nucleic Acids Res. 2015 Jan;43(2):1189-203
pubmed: 25550431
Gene Ther. 1997 Sep;4(9):891-900
pubmed: 9349425
J Am Chem Soc. 2014 May 28;136(21):7726-33
pubmed: 24841494
J Immunother. 2011 Jan;34(1):1-15
pubmed: 21150709
Bioconjug Chem. 2005 Sep-Oct;16(5):1240-5
pubmed: 16173804
Int J Pharm. 2020 Nov 30;590:119963
pubmed: 33039492
Nat Protoc. 2016 Jan;11(1):22-36
pubmed: 26633129
Colloids Surf B Biointerfaces. 2009 Oct 1;73(1):36-41
pubmed: 19481426
Gene Ther. 1997 Sep;4(9):961-8
pubmed: 9349433
J Gene Med. 2012 Jun;14(6):428-39
pubmed: 22262664
Front Genet. 2019 Oct 08;10:962
pubmed: 31649732
Nat Biotechnol. 2013 Jul;31(7):638-46
pubmed: 23792630
Adv Mater. 2015 Apr 8;27(14):2278-97
pubmed: 25728711
Sci Transl Med. 2012 Apr 18;4(130):130ra48
pubmed: 22517885
FASEB J. 2005 Sep;19(11):1555-7
pubmed: 16033808
Biomaterials. 2010 Feb;31(6):1429-43
pubmed: 19954842
Lancet. 2017 Sep 23;390(10101):1511-1520
pubmed: 28754494
Cancer Immunol Immunother. 2019 May;68(5):799-812
pubmed: 30770959
J Drug Target. 2021 Apr 7;:1-15
pubmed: 33775190
Nat Rev Genet. 2014 Aug;15(8):541-55
pubmed: 25022906
J Control Release. 2016 Oct 28;240:227-234
pubmed: 26718856
Gene Ther. 2003 Jan;10(1):5-14
pubmed: 12525832
Eur J Immunol. 2004 Feb;34(2):537-47
pubmed: 14768059
J Control Release. 2018 Jun 28;280:20-30
pubmed: 29723613
Biomaterials. 2014 Mar;35(9):3091-101
pubmed: 24406217
J Immunother Cancer. 2015 Jun 16;3:26
pubmed: 26082837
Eur J Immunol. 2005 May;35(5):1557-66
pubmed: 15832293
Gene Ther. 1998 Jul;5(7):930-7
pubmed: 9813664
Adv Healthc Mater. 2015 Jan 28;4(2):281-90
pubmed: 25044638
Nature. 1998 Feb 19;391(6669):806-11
pubmed: 9486653
Int J Nanomedicine. 2019 Jul 15;14:5287-5301
pubmed: 31406460
Chem Soc Rev. 2012 Apr 7;41(7):2718-39
pubmed: 22389111
Brief Funct Genomic Proteomic. 2007 Jun;6(2):112-9
pubmed: 17670766
Cancers (Basel). 2020 Mar 25;12(4):
pubmed: 32218299
Nat Biotechnol. 2005 Jun;23(6):709-17
pubmed: 15908939
Annu Rev Med. 2005;56:401-23
pubmed: 15660519
Biochemistry. 1996 Jan 23;35(3):1027-36
pubmed: 8547238
Science. 2004 Mar 5;303(5663):1529-31
pubmed: 14976261
J Exp Med. 2009 Aug 3;206(8):1717-25
pubmed: 19581407
J Immunother. 2009 Jun;32(5):498-507
pubmed: 19609242
Cancer Res. 2004 Nov 1;64(21):7668-72
pubmed: 15520166
Biochim Biophys Acta. 1983 May 5;730(2):313-20
pubmed: 6849906
Cells. 2020 Sep 05;9(9):
pubmed: 32899484
Asian J Pharm Sci. 2019 Sep;14(5):521-530
pubmed: 32104479
Nanomaterials (Basel). 2017 Apr 05;7(4):
pubmed: 28379201
J Immunother Cancer. 2019 Feb 8;7(1):38
pubmed: 30736848
Blood. 2010 Jun 3;115(22):4533-41
pubmed: 20304804